Bureaucrats May Stop Life-saving Meds from Reaching Canada
Sydney Otomancek2020-10-28T17:25:44-04:00October 28th, 2020|Categories: Featured, Industry News|Tags: Canada, Drug costs, HEOR, pharma, pricing|
If Canadian bureaucrats on the Patent Medicine Prices Review Board (PMPRB) get their way, innovative new drugs and vaccines may not come [...]
Receive essential insights, resources and content direct to your inbox!
Hit subscribe to stay informed!
Advertisement
Latest News
Featured Webinars
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches
Thursday, February 29, 2024
Sponsor: Carelon Research
Categories
Artificial Intelligence
Careers
Clinical Trials
Cost Effectiveness
Data Analytics & Syndicated Reports
Healthcare Financing
Health Databases
Health Equity
Health Policy
Health Tech Assessment
HEOR
Integrated Evidence Assessment & Planning
Market Access
Medical Affairs
Patient Outcomes & Engagement
Pricing & Reimbursement
Real World Data
Real World Evidence
Value Assessment
Value Communication